INNOVATION HUBS: EATRIS AND GLAXOSMITHKLINE EXTEND THEIR COLLABORATION FOR THREE ADDITIONAL YEARS

2020-08-05

In 2018, EATRIS-ERIC, GlaxoSmithKline (GSK) and five EATRIS member institutions (Academic Medical Center Amsterdam, Radboud University Medical Center Nijmegen, University Medical Center Groningen, VU University Medical Center Amsterdam from the Netherlands, and Uppsala University and Uppsala University Hospital from Sweden) announced the establishment of a novel international public-private partnership: The Translational Molecular Imaging Hub.

The Hub delivers a clinical and scientific expert network for the development and application of innovative imaging methods for inflammatory diseases. Applying imaging in information-rich, small cohort studies can provide a high, immediate impact to enhance the productivity of research and development: developing our understanding of disease in the patient; enriching clinical trial cohorts; measuring therapeutic response.

Now at the end of the initial collaboration period, EATRIS-ERIC, EATRIS member institutions and GSK, have expressed their commitment to continue their partnership for a minimum of three more years. Already, the Imaging Hub has built a mature project portfolio comprising of three preclinical projects and two clinical projects, which hold great translational potential. Partners are also involved in a joint PhD programme supported by the Marie Skłodowska Curie programme of Horizon 2020.